P/E ratio for QuidelOrtho (QDEL)
P/E ratio as of June 2023 (TTM): 46.7
According to QuidelOrtho's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 46.7297. At the end of 2021 the company had a P/E ratio of 8.04.
P/E ratio history for QuidelOrtho from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 8.04 | -13.99% |
| 2020 | 9.34 | -77.84% |
| 2019 | 42.2 | 70.96% |
| 2018 | 24.7 | -113.08% |
| 2017 | -188 | |
| 2015 | -125 | -13.76% |
| 2014 | -145 | -202.98% |
| 2013 | 140 | 12.81% |
| 2012 | 124 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Thermo Fisher Scientific TMO | 33.7 | -27.79% | 🇺🇸 USA |
 Becton Dickinson BDX | 47.1 | 0.76% | 🇺🇸 USA |
 Danaher DHR | 25.3 | -45.95% | 🇺🇸 USA |
 PerkinElmer
PKI | 25.1 | -46.26% | 🇺🇸 USA |
 OraSure Technologies OSUR | -21.2 | -145.31% | 🇺🇸 USA |
 Meridian Bioscience VIVO | 35.0 | -25.06% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.